Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia
- 7 April 1999
- journal article
- clinical trial
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 32 (5) , 331-335
- https://doi.org/10.1002/(sici)1096-911x(199905)32:5<331::aid-mpo4>3.0.co;2-m
Abstract
Background Intensification chemotherapy improves the prognosis for children with acute lymphoblastic leukemia (ALL), but results in considerable morbidity, primarily due to myelosuppression with resultant neutropenia. Recombinant granulocyte colony‐stimulating factor (G‐CSF) shortens neutropenia following intensive chemotherapy, but potential benefits in the therapy of ALL remain inadequately explored. Accordingly, a randomized, crossover study was undertaken to clarify this issue. Procedure Seventeen children with acute lymphoblastic leukemia or T‐cell non‐Hodgkin lymphoma and treated on standard protocols were randomized to receive G‐CSF following either the first or second intensification blocks of chemotherapy. G‐CSF was administered as a single daily subcutaneous injection of 5 mcg/kg from day 9 following the start of intensification therapy, and continued until the neutrophil count exceeded 0.5 × 109/l for 3 days. Study endpoints were days of neutropenia (neutrophils 9/l) and severe neutropenia (neutrophils 9/l), days in hospital, days of fever, and days on antibiotics. Results There were significant reductions in the duration of neutropenia (95% confidence interval 3.8–8 days, P = 0.0001), severe neutropenia (95% confidence interval 1.8–7.4 days, P = 0.002), and days in hospital (95% confidence interval 0.9–6.3 days, P = 0.01) for children receiving G‐CSF. Overall, the duration of neutropenia was longer following the second block (95% confidence interval 2.2–6.4 days, P = 0.0003), but this difference was abolished by G‐CSF, and children receiving G‐CSF after the second intensification were more likely to restart maintenance chemotherapy on schedule (P = 0.05). Conclusions G‐CSF reduces the hematological toxicity of intensification chemotherapy and may allow improved compliance with treatment scheduling. Med. Pediatr. Oncol. 32:331–335, 1999.Keywords
This publication has 20 references indexed in Scilit:
- Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study.Journal of Clinical Oncology, 1998
- Human Granulocyte Colony-Stimulating Factor after Induction Chemotherapy in Children with Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1997
- Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients.Journal of Clinical Oncology, 1997
- Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL XThe Lancet, 1995
- Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapyEuropean Journal Of Cancer, 1993
- Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trialBlood, 1992
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung CancerNew England Journal of Medicine, 1991
- Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (Report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood)British Journal of Haematology, 1991
- Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapyThe Lancet, 1991
- Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy.Journal of Clinical Oncology, 1989